ArticleEJHaem2025

Immune Signatures Identify Patient Subsets Deriving Long-Term Benefit From First-Line Rituximab in Follicular Lymphoma.

Ginevra Lolli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.